OLD Category: immuno-oncology

September 27, 2023 / Cancer Res Commun

  • Ye J, Guo W, Wang C, Egelston CA, D'Apuzzo M, Shankar G, Fakih MG, Lee PP
Microsatellite stable (MSS) colorectal cancer (CRC) patients with liver metastases are resistant to immune checkpoint inhibitor (ICI) therapy, while about one-third of CRC patients without liver metastases, particularly those with…
September 27, 2023 / Oncoimmunology

  • Martinez-Morilla S, Myrto Moutafi, Aileen I. Fernandez, Shlomit Jessel, Prajan Divakar, Pok Fai Wong, Rolando Garcia-Milian, Kurt A. Schalper, Harriet M. Kluger & David L. Rimm
Although immune checkpoint inhibitor (ICI) therapy has dramatically improved outcome for metastatic melanoma patients, many patients do not benefit. Since adverse events may be severe, biomarkers for resistance would be…
September 20, 2023 / Oncoimmunology

  • Go EJ, Yang H, Lee SJ, Yang HG, Shin JA, Lee WS, Lim HS, Chon HJ, Kim C
Antiangiogenic therapy is a recognized method for countering the immunosuppressive tumor microenvironment (TME) and improving anti-tumor immunity. PB101 is a glycosylated decoy receptor that binds to VEGF-A and PlGF with…
September 19, 2023 / Clin Cancer Res

  • Deng N, Reyes-Uribe L, Fahrmann JF, Thoman WS, Munsell MF, Dennison JB, Murage E, Wu R, Hawk ET, Thirumurthi S, Lynch PM, Dieli-Conwright CM, Lazar AJ, Jindal S, Chu K, Chelvanambi M, Basen-Engquist K, Li Y, Wargo JA, McAllister F, Allison JP, Sharma P, Sinha KM, Hanash S, Gilchrist SC, Vilar E
Purpose: Lynch Syndrome (LS) is a hereditary condition with a high lifetime risk of colorectal and endometrial cancers. Exercise is a non-pharmacological intervention to reduce cancer risk, though its impact…
September 14, 2023 / Gut

  • van Eijck CWF, Mustafa DAM, Vadgama D, de Miranda NFCC, Groot Koerkamp B, van Tienhoven G, van der Burg SH, Malats N, van Eijck CHJ; Dutch Pancreatic Cancer Group (DPCG)
Background: This study investigates sex disparities in clinical outcomes and tumour immune profiles in patients with pancreatic ductal adenocarcinoma (PDAC) who underwent upfront resection or resection preceded by gemcitabine-based neoadjuvant…
August 29, 2023 / J Transl Med

  • Liu G, Wang L, Ji L, He D, Zeng L, Zhuo G, Zhang Q, Wang D, Pan Y
Profiling (DSP) technology to analyze transcripts from 107 regions of interest in 65 untreated breast cancer tissue samples. Our study revealed spatial heterogeneity in the expression of marker genes in…
August 25, 2023 / iScience

  • Ying L, Zhang C, Reuben A, Tian Y, Jin J, Wang C, Bai J, Liu X, Fang J, Feng T, Xu C, Zhu R, Huang M, Lyu Y, Lu T, Pan X, Zhang J, Su D
The immunogenomic features of tumor-adjacent lungs (TALs) in stage I lung squamous cell carcinoma (LUSC) are not clear. Multiomics analyses of tumor tissues and paired TALs from 59 stage I…
August 23, 2023 / Front Immunol

  • Tripodo C, Bertolazzi G, Cancila V, Morello G, Iannitto E
We have established a pseudotemporal ordering for the transcriptional signatures of distinct microregions within reactive lymphoid tissues, namely germinal center dark zones (DZ), germinal center light zones (LZ), and peri-follicular…
August 16, 2023 / Cancers (Basel)

  • Gerton TJ, Green A, Campisi M, Chen M, Gjeci I, Mahadevan N, Lee CAA, Mishra R, Vo HV, Haratani K, Li ZH, Hasselblatt KT, Testino B, Connor T, Lian CG, Elias KM, Lizotte P, Ivanova EV, Barbie DA, Dinulescu DM
Simple Summary: The clinical implementation of novel precision medicine strategies in high-grade serous ovarian cancer (HGSOC), the most common and aggressive ovarian cancer subtype, are urgently needed. Targeted immunotherapeutic combinations…
August 15, 2023 / Cell Rep Med

  • Chang YW, Hsiao HW, Chen JP, Tzeng SF, Tsai CH, Wu CY, Hsieh HH, Carmona SJ, Andreatta M, Di Conza G, Su MT, Koni PA, Ho PC, Chen HK, Yang MH
Strategies to increase intratumoral concentrations of an anticancer agent are desirable to optimize its therapeutic potential when said agent is efficacious primarily within a tumor but also have significant systemic…
July 17, 2023 / Hepatol Commun

  • Yamada T, Fujiwara N, Kubota N, Matsushita Y, Nakatsuka T, Kurosaki S, Minami T, Tateishi R, Ichida A, Arita J, Hasegawa K, Koike K, Fujishiro M, Nakagawa H
Background: Lenvatinib was expected to enhance the effect of immune checkpoint inhibitors (ICIs) for unresectable HCC; however, their combination therapy failed to show the synergy in the phase III clinical…
June 29, 2023 / Int J Mol Sci

  • Huntington KE, Louie AD, Srinivasan PR, Schorl C, Lu S, Silverberg D, Newhouse D, Wu Z, Zhou L, Borden BA, Giles FJ, Dooner M, Carneiro BA, El-Deiry WS
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase that has been implicated in numerous oncogenic processes. GSK-3 inhibitor elraglusib (9-ING-41) has shown promising preclinical and clinical antitumor activity across multiple…